Cullinan, Taiho Present Zipalertinib Phase 2b Results at ASCO 2025
May 26, 2025
Cullinan Therapeutics, Inc., Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, announced new positive results from the pivotal Phase 2b cohorts of the REZILIENT1 trial, a Phase
